APLS - Apellis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.84
-0.37 (-2.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.21
Open14.35
Bid13.44 x 1100
Ask19.98 x 800
Day's Range13.63 - 14.44
52 Week Range11.45 - 32.00
Volume207,947
Avg. Volume299,570
Market Cap778.398M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.28
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.40
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Apellis Pharmaceuticals, Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on February 11, 2019, the Compensation Committee of the Board of Directors approved the grant of equity awards to a new employee, as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and material to the employee's acceptance of employment with the Company. The employee received, in the aggregate, options to purchase 120,000 shares of Apellis common stock. The options have an exercise price of $13.72 per share, which is equal to the closing price of Apellis common stock on February 11, 2019.

  • GlobeNewswire8 days ago

    Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s APL-2, a novel inhibitor of complement factor C3, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). APL-2 is currently being studied in a Phase 3 active comparator trial in patients with PNH who remain anemic despite treatment with eculizumab.

  • GlobeNewswire13 days ago

    Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia

    Apellis Pharmaceuticals Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of autoimmune hemolytic anemia (AIHA).

  • GlobeNewswire19 days ago

    Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe

    Apellis Pharmaceuticals, Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced today the appointment of Thomas Lackner as Senior Vice President, Head of Europe. Prior to joining Apellis, Thomas was responsible for developing the global commercial strategy and launch organization for Prothena Biosciences in Europe, for their first global launch in a hematologic rare disease (AL amyloidosis).

  • Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher
    Zackslast month

    Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher

    Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • GlobeNewswire2 months ago

    Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials.

  • Is Apellis Pharmaceuticals, Inc. (APLS) A Good Stock To Buy?
    Insider Monkey2 months ago

    Is Apellis Pharmaceuticals, Inc. (APLS) A Good Stock To Buy?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • GlobeNewswire2 months ago

    Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy

    Apellis Pharmaceuticals Inc., (APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation by the FDA for the treatment of C3 glomerulopathy (C3G). C3 glomerulopathy refers to a group of rare renal disorders in which hyperactivity of the complement system leads to deposition of C3 in the glomeruli, the portion of the kidney responsible for blood filtration. C3G is a disease with a high unmet need, as approximately half of all patients with C3G progress to end-stage renal disease within 10 years of diagnosis, and there is no approved therapy proven to prevent progression.

  • GlobeNewswire2 months ago

    Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy

    Apellis Pharmaceuticals Inc. (APLS) today provided an update on the status of its Phase 3 program for APL-2 in patients with Geographic Atrophy (GA). Apellis expects to be able to restart enrollment of its two Phase 3 GA trials (DERBY & OAKS) in Q2 2019 and to have fully enrolled both studies by the end of Q1 2020, within the originally planned timeline for completion. As previously disclosed, the Company voluntarily implemented a temporary pause in dosing in the DERBY and OAKS Phase 3 trials due to observed cases of non-infectious inflammation in patients treated from a single manufacturing lot of APL-2 intravitreal drug product.

  • Benzinga2 months ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    Biotech stocks staged a modest comeback this week ending along with the broader market. The week saw a spate of clinical trial results releases , sending stocks moving in either direction. The tally of ...

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH

    -  New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) -  CAD patients.

  • GlobeNewswire3 months ago

    Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH

    Apellis Pharmaceuticals Inc. (APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced interim data from its Phase 1b study of APL-2 in treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). Data from the PADDOCK trial were presented in a poster session today at the 60th Annual Meeting of the American Society of Hematology (ASH).

  • Enable Injections inks development deals with pharma firms
    American City Business Journals3 months ago

    Enable Injections inks development deals with pharma firms

    Enable Injections has entered into separate development agreements with two more companies, Apellis Pharmaceuticals and UCB.

  • Apellis shares plunge after incident in two clinical trials
    American City Business Journals4 months ago

    Apellis shares plunge after incident in two clinical trials

    Apellis Pharmaceuticals Inc.'s share price dropped sharply Thursday after the company disclosed that it had temporarily halted human testing of its signature treatment in two clinical trials. In mid-afternoon trading, Apellis (Nasdaq: APLS) shares were down $3.14, or about 19 percent, at $13.57. The Crestwood, Ky.-based biopharmaceutical company, which is conducting late-stage clinical trials of the treatment, disclosed in a Securities and Exchange Commission filing Wednesday that eight patients developed cases of non-infectious inflammation after having the drug injected into their eyes.

  • EXCLUSIVE: Apellis CEO says company has no plans to move its HQ
    American City Business Journals5 months ago

    EXCLUSIVE: Apellis CEO says company has no plans to move its HQ

    The CEO of Louisville's only publicly traded biopharmaceutical company says he'll keep its headquarters in Louisville, but has to grow specific operations in other locations.